TaiMed Biologics Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	607.22	610.16	491.78	563.01	413.44	722.49
Revenue Growth (YoY)	-2.47%	24.07%	-12.65%	36.18%	-42.77%	2.55%
Cost of Revenue	381.39	398.94	266.54	347.3	329.49	311.77
Gross Profit	225.83	211.23	225.23	215.71	83.96	410.71
Selling, General & Admin	68.57	75.29	97.19	74.45	109.72	59.55
Research & Development	393	388.21	294.28	333.12	460.6	394.45
Other Operating Expenses	-	-	-	-	-	89.47
Operating Expenses	461.57	463.49	391.46	407.57	570.32	543.47
Operating Income	-235.74	-252.27	-166.23	-191.86	-486.37	-132.76
Interest Expense	-11.22	-12.6	-14.81	-10.1	-7.44	-4.09
Interest & Investment Income	30.31	33.97	8.46	4.34	4.03	8.48
Currency Exchange Gain (Loss)	-6.01	26.35	2.04	48.69	-11.38	2.47
Other Non Operating Income (Expenses)	5.74	5.05	4.78	2.44	3.45	4.35
EBT Excluding Unusual Items	-216.92	-199.51	-165.76	-146.48	-497.7	-121.55
Gain (Loss) on Sale of Investments	-1.18	-	-29.05	-122.81	26.76	-63.13
Gain (Loss) on Sale of Assets	-1.61	-2.32	-	-	0.01	1.37
Pretax Income	-219.71	-201.83	-194.81	-269.29	-470.93	-183.3
Net Income	-219.71	-201.83	-194.81	-269.29	-470.93	-183.3
Net Income to Common	-219.71	-201.83	-194.81	-269.29	-470.93	-183.3
Shares Outstanding (Basic)	273	268	253	252	252	252
Shares Outstanding (Diluted)	273	268	253	252	252	252
Shares Change (YoY)	3.78%	6.08%	0.18%	0.04%	0.03%	0.07%
EPS (Basic)	-0.80	-0.75	-0.77	-1.07	-1.87	-0.73
EPS (Diluted)	-0.80	-0.75	-0.77	-1.07	-1.87	-0.73
Free Cash Flow	-349.13	-387.61	-31.75	-608.77	-220.96	-255.55
Free Cash Flow Per Share	-1.28	-1.45	-0.13	-2.41	-0.88	-1.01
Gross Margin	37.19%	34.62%	45.80%	38.31%	20.31%	56.85%
Operating Margin	-38.82%	-41.34%	-33.80%	-34.08%	-117.64%	-18.38%
Profit Margin	-36.18%	-33.08%	-39.61%	-47.83%	-113.90%	-25.37%
Free Cash Flow Margin	-57.50%	-63.52%	-6.46%	-108.13%	-53.44%	-35.37%
EBITDA	-87.72	-104.49	-17.72	-42.22	-336.3	2.3
EBITDA Margin	-14.45%	-17.13%	-3.60%	-7.50%	-81.34%	0.32%
D&A For EBITDA	148.02	147.78	148.51	149.64	150.07	135.06
EBIT	-235.74	-252.27	-166.23	-191.86	-486.37	-132.76
EBIT Margin	-38.82%	-41.34%	-33.80%	-34.08%	-117.64%	-18.38%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.